ClinicalTrials.gg
RecruitingNCT05709132iP2P HFUpdated Nov 19, 2026

iP2P Mentorship Program for Adolescent HF Patients

An interventional study of iPeer2Peer Program in Heart Failure, sponsored by The Hospital for Sick Children. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
12 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 454 studies in Heart Failure with a site in Canada — 77 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Canada.

Planned enrollment
280th of 362
55 · median 226
Started
2024
with 26 others
No phase
162 of 454
31 open now
Primary completion
2027-04
later than 48 of 98 live
Registered
387th of 454
by date

Among the 454 studies in Heart Failure with a site in Canada, this one is the 280th largest by planned enrollment of the 362 interventional ones that give a count, is one of 27 that started in 2024, is one of 162 with no phase, reaches primary completion later than 48 of the 98 other live ones, and was the 387th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

77 of the 454 studies in Heart Failure with a site in Canada are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 12 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Heart Failure with a site in Canada, or all of them as a file.
02

Study summary

The iPeer2Peer (iP2P) program is an online peer support mentorship program that provides modelling and reinforcement by trained young adult peer mentors to adolescent mentees with the same condition. A quasi-experimental single-arm pre-post study design will be employed across three sites. We will recruit 40 mentees (12-17 years of age) and 12-15 mentors (18-30 years of age) who will undergo training in mentoring and the use of eHealth technology. Mentor-mentee pairings will connect over 15 weeks through video calls and text messaging to provide peer support and encourage disease self-management skills. Data will be collected using standardized instruments and interviews across three time points.

03

Conditions studied

  • Heart Failure

Keywords

  • Peer Support Mentorship
  • Pediatrics
  • Adherence
  • Cardiomyopathy
04

Who can participate

Ages eligible
12 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Mentee inclusion criteria:

  1. patient with a cardiac diagnosis,
  2. at least 4 months post-diagnosis,
  3. between the ages of 12 and 17 years,
  4. able to speak and read English, and
  5. willingness to commit to 5-10 texts and/or calls of 20-30 minutes each with a peer mentor over a period of 15 weeks.

Mentor inclusion criteria:

  1. patient with a cardiac diagnosis,
  2. between the ages of 18 and 30 years,
  3. able to speak and read English,
  4. nominated by a member of their health care team as a good mentor based on maturity and emotional stability,
  5. willingness to commit to peer mentor training (20 hours) via the PHIPA-compliant version of Zoom or Microsoft Teams and mentoring adolescent participants (once paired with mentee, 5-10 texts and/or calls of 20-30 minutes over a period of 15 weeks),
  6. good communication skills (as assessed by a healthcare provider), and
  7. previous experience in a professional environment (e.g., as a camp counsellor, part time job, volunteering) is an asset.

Exclusion Criteria:

  1. significant cognitive impairments as assessed by a qualified healthcare provider,
  2. a diagnosis of an active psychological disorder (e.g., Major Depressive Disorder, Generalized Anxiety Disorder) likely to influence assessment of health-related quality of life and/or interfere with their ability to manage their heart failure care regimen (a diagnosis of an active psychological disorder will be determined for mentees through medical chart review and self-reported by mentors), and
  3. participating in other peer support or self-management interventions.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    iPeer2Peer Program

    Participates in the iPeer2Peer program

    Behavioral: iPeer2Peer Program

Interventions

  • BehavioraliPeer2Peer Program

    Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.

06

What researchers measure

Primary outcomes

  1. Acceptability (Mentees)

    Whether the innovation is agreeable, palatable or satisfactory

    Time frame: 15 weeks after baseline/immediately after the intervention

  2. Acceptability (Mentors)

    Whether the innovation is agreeable, palatable or satisfactory

    Time frame: Study completion, an average of 1 year

  3. Adoption (Mentees)

    The intention, initial decision or action to try or use an innovation

    Time frame: Baseline to 12 weeks post-program completion

  4. Adoption (Mentors)

    The intention, initial decision or action to try or use an innovation

    Time frame: Baseline to study completion, an average of 1 year

  5. Feasibility (Mentees)

    The extent to which an innovation can be used or carried out successfully in a given setting

    Time frame: Baseline to 12 weeks post-program completion

  6. Feasibility (Mentors)

    The extent to which an innovation can be used or carried out successfully in a given setting

    Time frame: Baseline to study completion, an average of 1 year

  7. Appropriateness (Mentees)

    The perceived fit, relevance or compatibility of the innovation for a practice setting; and/or its perceived fit to address an issue or problem

    Time frame: Baseline to 12 weeks post-program completion

  8. Appropriateness (Mentors)

    The perceived fit, relevance or compatibility of the innovation for a practice setting; and/or its perceived fit to address an issue or problem

    Time frame: Baseline to study completion, an average of 1 year

  9. Level of engagement (Mentees)

    Time frame: 15 weeks after baseline/immediately after the intervention

  10. Level of engagement (Mentors)

    Time frame: Study completion, an average of 1 year

Secondary outcomes

  1. Disease self-management skills (Mentees)

    Time frame: Baseline to 12 weeks post-program completion

  2. Adherence (Mentees)

    Clinic attendance, completion of scheduled tests and procedures, and adolescent medication barriers scale

    Time frame: Baseline to 12 weeks post-program completion

  3. Quality of life (Mentees)

    Time frame: Baseline to 12 weeks post-program completion

  4. Perceived social support (Mentees)

    Time frame: Baseline to 12 weeks post-program completion

  5. Emotional distress (Mentees)

    Time frame: Baseline to 12 weeks post-program completion

  6. Resiliency (Mentees)

    Time frame: Baseline to 12 weeks post-program completion

  7. Assessment of mentor quality (Mentees)

    Time frame: 15 weeks after baseline/immediately after the intervention

  8. Physical and emotional symptoms (Mentors)

    Time frame: Baseline to study completion, an average of 1 year

  9. Perceived social role satisfaction (Mentors)

    Time frame: Baseline to study completion, an average of 1 year

  10. Self-efficacy (Mentors)

    Time frame: Baseline to study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 39 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2023
First posted
Feb 1, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Apr 13, 2027
CompletionEst.
Apr 13, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and site details
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05709132
Collaborators
The Centre Hospitalier Universitaire Sainte-Justine, University of Alberta/Stollery Children's Hospital
Responsible party
Samantha Anthony (Principal Investigator, The Hospital for Sick Children) — Principal investigator
First posted
Feb 1, 2023
Start date
Jan 1, 2024
Primary completion
Apr 13, 2027 (estimated)
Completion
Apr 13, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Samantha J Anthony, PhD
Contact
samantha.anthony@sickkids.ca
416-813-7654 ext. 303126
Sophie Bui, BHSc
Contact
sophie.bui@sickkids.ca
Samantha J Anthony, PhD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion